Jiali Luo

Jiali Luo

Auto-generated profile, based on publicly available information

Jiali Luo

Department of Ultrasound in Medicine, The Second Affiliated Hospital of Zhejiang University School of Medicine, No. 88 Jiefang Road, Shangcheng District, Hangzhou 310009, P. R. China

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 August 2022 in ACS Applied Materials & Interfaces
Verified
Journal Article
Closed access
JLJiali Luo
Jiali Luo
JCJing Cao
Jing Cao
GMGuangrong Ma
Guangrong Ma
XWXue Wang
Xue Wang
YSYu Sun
Yu Sun
PHPin-tong HUANG
Pin-tong HUANG

26 January 2023 in ACS Applied Materials & Interfaces
Verified
Journal Article
Closed access
XWXue Wang
Xue Wang
JLJiali Luo
Jiali Luo
JWJing Wang
Jing Wang
JCJing Cao
Jing Cao
YHYurong Hong
Yurong Hong
PHPin-tong HUANG
Pin-tong HUANG

10 October 2024 in ACS Nano
Verified
Journal Article
Closed access
ZSZhan Shi
Zhan Shi
YZYiqing Zeng
Yiqing Zeng
JLJiali Luo
Jiali Luo
XWXue Wang
Xue Wang
GMGuangrong Ma
Guangrong Ma
PHPin-tong HUANG
Pin-tong HUANG

10 January 2023 in Nano Research
Verified
Journal Article
Closed access
PDF file
ZSZhan Shi
Zhan Shi
XWXue Wang
Xue Wang
JLJiali Luo
Jiali Luo
YZYiqing Zeng
Yiqing Zeng
QWQing Wen
Qing Wen
PHPin-tong HUANG
Pin-tong HUANG
Mitochondria-targeted sonodynamic therapy (SDT) is a promising strategy to inhibit tumor growth and activate the anti-tumor immune responses. Identifying the mechanisms underlying mitochondria-targeted SDT, further optimizing its efficacy, and developing novel sonosensitizer carriers with good biocompatibility pose major challenges to the clinical practice of SDT. In this study, we investigated the mechanisms of mitochondria-targeted SDT and demonstrated that it suppressed the mitochondrial electron transport chain (ETC) in pancreatic cancer cells through RNA-sequencing analysis. Based on these findings, we constructed the functional lipid droplets (LDs) (CPI-613/IR780@LDs), which combined mitochondria-targeted SDT with the tricarboxylic acid (TCA) cycle inhibitor CPI-613. CPI-613/IR780@LDs synergistically inhibited the TCA cycle and the ETC of mitochondrial aerobic respiration to reduce oxygen consumption and increase reactive oxygen species (ROS) generation at the tumor site, thus enhancing the efficacy of SDT in hypoxic pancreatic cancer. Moreover, the combination of mitochondria-targeted SDT and anti-PD-1 antibody exhibited excellent tumor inhibition and activated anti-tumor immune responses by increasing tumor-infiltrating CD8+ T cells and reducing regulatory T cells, synergistically arresting the growth of both primary and metastatic pancreatic tumors. Meanwhile, lipid droplets are cell-derived biological carriers with natural mitochondrial targeting ability and can achieve efficient hydrophobic drug loading through active phagocytosis. Therefore, the functional lipid droplet-based SDT combined with anti-PD-1 antibody holds great potential in the clinical treatment of hypoxic pancreatic cancer.

8 March 2022 in Frontiers in Oncology
Verified
Journal Article
Open access
LZLisi Zeng
Lisi Zeng
XHXubo Huang
Xubo Huang
YTYun Tian
Yun Tian
JHJinxia Huang
Jinxia Huang
HLHuiyan Liu
Huiyan Liu
SCShuzhong Cui
Shuzhong Cui
Background: Gastric cancer (GC) is one of the most common cancer types, especially in Asian countries. Hyperthermic intraperitoneal chemotherapy (HIPEC) has been shown to improve the progression-free survival among gastric cancer patients with peritoneal metastases; however, not all patients demonstrate response to HIPEC.Methods: Biomarkers are needed to select patients for effective treatment of HIPEC. Here, we performed whole-exome sequencing on tumor samples from 18 gastric cancer patients who received HIPEC treatment and assessed the association between genomic mutation features and progression-free survival. Exome sequencing was further conducted on tumor samples from additional 15 gastric cancer patients as a replication study.Results: The tumor mutational burden (TMB) was significantly higher in the group of patients with a better response to HIPEC treatment than that of the others. Kaplan–Meier survival curve showed that patients with high TMB had a significantly longer survival time than that in patients with low TMB. This discovery was validated in the replication cohort. Genes bearing mutations recurrently and selectively in patients with better response to HIPEC were found in the two cohorts.Conclusion: We found that higher TMB is significantly associated with better response to HIPEC. Our results provide useful hints for prognostic stratification of HIPEC treatment.

2 March 2020 in Chinese Science Bulletin
Verified
Journal Article
Open access
DMDongchuan MO
Dongchuan MO
JLJiali Luo
Jiali Luo
YWYaqiao Wang
Yaqiao Wang
Yi HengYi Heng
Yi Heng
YFYuan-Xiang Fu
Yuan-Xiang Fu
SLShu-shen LYU
Shu-shen LYU